Description
Ef5 is currently under investigation for use in metastatic colorectal cancer as a targeted therapy. It has shown promising results in preclinical studies but its efficacy and safety profile are still being evaluated in clinical trials.
Mechanism of Action
Ef5 is an investigational agent that targets the epidermal growth factor receptor (EGFR) in colorectal cancer cells, inhibiting cell proliferation and angiogenesis.
Side Effects
Hypertension; Diarrhea; Rash; Fatigue
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT00087191
Not Applicable
Terminated
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
United States
Quick Info
| Category | Terapia Dirigida |
 Estado EMA | Experimental |
 Acceso España | med_spain_not_available |
| Clinical Trials | 1 |
Related Medications
Midostauri
Terapia Dirigida
1 trials
PLD
Terapia Dirigida
1 trials
Impac
Terapia Dirigida
1 trials
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.